drugset / Trial / NCT00559715
Prevention of Vision Loss in Patients With Age-Related Macular Degeneration (AMD) by Intravitreal Injection of Bevacizumab and Ranibizumab
Phase 3
Unknown
366 enrolled
Klinikum Bremen-Mitte, gGmbH
Kompetenzzentrum für Klinische Studien, Bremen · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The study is designed to demonstrate the therapeutic non-inferiority of the recombinant humanized monoclonal VEGF antibody bevacizumab administered by intravitreal injection in the treatment of AMD in comparison to the related fragment ranibizumab.
Timeline
- Start
- 2008-08
- Primary completion
- 2009-08
- Completion
- 2010-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 1.25 mg | Intravitreal |
| Comparator | Ranibizumab | Monoclonal antibody | 0.5 mg | Intravitreal |